Role of Serotonin Neurons in L-DOPA- and Graft-Induced Dyskinesia in a Rat Model of Parkinson's Disease by Shin, Eunju et al.
Hindawi Publishing Corporation
Parkinson’s Disease
Volume 2012, Article ID 370190, 5 pages
doi:10.1155/2012/370190
Review Article
Role of Serotonin Neurons in L-DOPA- and Graft-Induced
Dyskinesiaina Rat Modelof Parkinson’s Disease
EunjuShin,1 ElisabettaTronci,2 andManoloCarta2
1Division of Neurobiology, Wallenberg Neuroscience Center, Lund University, 221 84 Lund, Sweden
2Department of Biomedical Science, Cagliari University, Cittadella Universitaria, SS 554 km 4.500, 09042 Monserrato, Italy
Correspondence should be addressed to Manolo Carta, manolocarta@unica.it
Received 16 February 2012; Revised 2 April 2012; Accepted 10 April 2012
Academic Editor: Gilberto Fisone
Copyright © 2012 Eunju Shin et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
L-DOPA, the most eﬀective drug to treat motor symptoms of Parkinson’s disease, causes abnormal involuntary movements,
limiting its use in advanced stages of the disease. An increasing body of evidence points to the serotonin system as a key player in
the appearance of L-DOPA-induced dyskinesia (LID). In fact, exogenously administered L-DOPA can be taken up by serotonin
neurons, converted to dopamine and released as a false transmitter, contributing to pulsatile stimulation of striatal dopamine
receptors.Accordingly,destructionofserotoninﬁbersorsilencingserotoninneuronsbyserotoninagonistscouldcounteractLIDin
animal models. Recent clinical work has also shown that serotonin neurons are present in the caudate/putamen of patients grafted
with embryonic ventral mesencephalic cells, producing intense serotonin hyperinnervation. These patients experience graft-
induced dyskinesia (GID), a type of dyskinesia phenotypically similar to the one induced by L-DOPA but independent from its
administration. Interestingly, the 5-HT1A receptor agonist buspirone has been shown to suppress GID in these patients, suggesting
that serotonin neurons might be involved in the etiology of GID as for LID. In this paper we will discuss the experimental and
clinical evidence supporting the involvement of the serotonin system in both LID and GID.
1.Introduction
Parkinson’s disease (PD) is the second most common neuro-
degenerativediseaseandischaracterizedbylossofdopamine
(DA) neurons in the substantia nigra. The cell loss results
in decreased activation of striatal DA receptors, thus causing
motor impairments, such as tremor, rigidity, bradykinesia,
and postural instability. The DA precursor L-3,4-dihydroxy-
phenylalanine (L-DOPA) represents the most eﬀective drug
to alleviate the motor symptoms. Although this medication
is very eﬃcient during the ﬁrst few years of administration,
its eﬃcacy gradually diminishes overtime, and uncontrolled
excessive movements, known as dyskinesia, appear as a side
eﬀect after a variable number of years in most of patients,
limiting the use of L-DOPA in advanced stages of the disease.
A better understanding of the mechanisms underlying
theappearanceofdyskinesiahasbeenachievedduringrecent
years using animal models of L-DOPA-induced dyskinesia
(LID). In fact, abnormal involuntary movements (AIMs)
develop in response to sub-chronic L-DOPA treatment in
6-hydroxydopamine (6-OHDA)-lesioned rats and 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mon-
keys, resembling peak-dose dyskinesia seen in patients [1–
4]. Using these models, a number of alterations have been
identiﬁed at the level of striatal neurons of dyskinetic sub-
jects, such as abnormal traﬃcking of DA D1 and N-methyl-
D-aspartate (NMDA) receptors [5, 6], leading to alterations
in key striatal signaling pathways.
More recently, the serotonin system has emerged as a
putative player in the induction of ﬂuctuations in synaptic
DA levels following administration of L-DOPA in animal
modelsofPD,whichcausepulsatilestimulationofDArecep-
tors and promote the maladaptive changes that characterize
the parkinsonian dyskinetic brain [7–11]. The emerging role
of serotonin neurons in LID has also prompted researchers
to investigate a possible involvement of these neurons in
the appearance of oﬀ-drug dyskinesia that has emerged in
a subset of PD patients following transplantation of fetal2 Parkinson’s Disease
ventral mesencephalic DA neuroblasts, namely, graft-
induced dyskinesia (GID) [12, 13]. In this paper, we will
discuss the recent experimental and clinical evidence sup-
porting a role of serotonin neurons both in LID and GID.
2. The Role of Serotonin Neurons in
theInductionofL-DOPA-InducedDyskinesia
Progression of DA neuron degeneration represents the ﬁrst
risk factor for development of LID in patients. In fact,
the eﬃcacy of L-DOPA in providing its therapeutic eﬀect
during the ﬁrst years of administration is conceivably due
to the ability of spared DA neurons to take up exogenously
administered L-DOPA, convert it to DA, and release it into
the synaptic cleft, but also to regulate synaptic DA levels via
the D2 autoreceptor and DA transporter (DAT). When the
disease is in its early stage, suﬃcient DA terminals remain
in the striatum to eﬃciently mediate a feedback-controlled
mechanism of release. The ability of the spared DA terminals
to prevent development of AIMs upon L-DOPA treatment is
well demonstrated in a recent report by Ulusoy et al. [14]. In
this study, a signiﬁcant DA deﬁciency was established in rats
by viral vector delivery of short hairpin RNA for the tyrosine
hydroxylase (TH) enzyme, without aﬀecting cell survival.
Animals were then made dyskinetic by subchronic treatment
with the direct DA agonist apomorphine; however, when
treated with L-DOPA, the same rats appeared to be fully
resistant to the induction of LID, despite apomorphine treat-
ment had already promoted postsynaptic alterations, such as
increased striatal FosB expression.
The ability of the presynaptic DA compartment to pre-
vent excessive DA receptor stimulation, and aberrant down-
stream signaling, even in presence of supersensitive striatal
DA receptors is also conﬁrmed in transplantation studies.
In fact, ventral mesencephalic DA graft, which reconstitutes
the presynaptic buﬀering capacity into the lesioned and
maladapted striatum, normalizes the response of L-DOPA-
primed dyskinetic rats to L-DOPA administration [7]. In
light with these results, it is conceivable to think that the
eﬃcacy of L-DOPA during the ﬁrst years of administration is
alsoduetothepresenceofasuﬃcientnumberofDAneurons
that can buﬀer the exogenously administered L-DOPA, and
provide a source of regulated DA release. However, with
the progression of DA degeneration, this buﬀering capacity,
and thus the ability to provide physiological level of DA
receptor stimulation, is progressively lost. In this situation,
the serotonin neurons come to play a major role in L-DOPA-
derived DA production and release, as they possess both
the aromatic amino acid decarboxylase enzyme (AADC)
and the vesicular monoamine transporter (VMAT). Unlike
DA neurons, though, serotonin neurons cannot regulate the
extracellularlevelsofDAduetothelackoftheautoregulatory
loop, hence, causing un-controlled DA release following
L-DOPA administration. DA released from serotonin neu-
ronswillthereforeactinconcertwiththeintermittentnature
of the orally administered L-DOPA to cause pulsatile stim-
ulation of DA receptors, and thus, changes in downstream
signaling pathways at striatal neurons. In support of this
view, removal of serotonin innervation by toxin lesion was
shown to produce about 80% reduction in L-DOPA-derived
striatal extracellular DA levels [15], and to induce a near-
to-complete suppression of LID in dyskinetic rats [8, 16].
Accordingly, pharmacological silencing of serotonin neuron
activity by 5-HT1A and 5-HT1B receptor agonists has been
shown to reduce L-DOPA-derived extracellular DA levels
[17], and to suppress LID in rats [8]a sw e l la si nM P T P -
treated monkeys [18]. In addition, chronic administration of
the 5-HT1 agonists was able to prevent the development of
dyskinesia and upregulation of FosB expression in the stria-
tumof6-OHDA-lesionedrats[18],thuslinkingdysregulated
DA release from serotonin terminals with the induction of
a well-known striatal marker of dyskinesia. Interestingly,
simultaneousactivationof5-HT1A and5-HT1B receptorswas
found to trigger a potent synergistic eﬀect in the suppression
o fL I Di nb o t hr a t sa n dm o n k e y s[ 8, 18]. In fact, LID was
nearlyfullyabolishedatdosesofcombinedagoniststhatwere
ineﬀective when given individually. This ﬁnding has now
led to the initiation of a ﬁrst double-blind, proof-of-concept
clinical trial employing a mixed 5-HT1A/1B receptor agonist
in dyskinetic patients.
In conﬁrming the interaction between exogenously
administered L-DOPA and serotonin neurons, Navailles
and coworkers have recently demonstrated that serotonin
neuron-dependent DA release takes place, upon chronic
L-DOPA treatment in 6-OHDA-lesioned rats, not only in the
striatum but also in other brain areas receiving suﬃcient
serotonin innervation, such as substantia nigra, hippocam-
pus, and prefrontal cortex [19]. Moreover, L-DOPA admin-
istration appears to result in reduced striatal serotonin tissue
content in 6-OHDA-lesioned rats [8]. The latter result sup-
ports the existence of a competition between serotonin and
DA for serotonergic vesicles, which causes serotonin deple-
tion. Thus, an increasing body of experimental evidence
points to the serotonin system as a key player in the appear-
ance of LID.
Progressive reduction of L-DOPA-derived extracellular
DA levels upon chronic L-DOPA treatment has been recently
found in 6-OHDA-lesioned rats [20, 21], leading some
researcher to question the role of serotonin neurons in the
appearance of LID [21]. Nevertheless, we believe that the
potent inhibitory eﬀect of 5,7-dihydroxytryptamine (5,7-
DHT) lesion on both development and expression of dyskin-
esia in 6-OHDA-lesioned rats [8], together with the striking
suppression of LID induced by low doses of 5-HT1A +5 -
HT1B receptor agonists both in rats and macaques [18]p r o -
videdunquestionableevidencesupportinganimportantrole
of serotonin neurons, at least in animal models of PD. It
shouldbetakenintoaccountthatduringchronicadministra-
tion of L-DOPA, postsynaptic DA receptors become super-
sensitive; thus, the dyskinetic response to L-DOPA might
be maintained by lower extracellular DA levels once postsy-
naptic alterations have been already induced. The relevance
for the human disease of the progressive reduction of extra-
cellular DA levels seen upon chronic L-DOPA in the rat
6-OHDA model remains to be established, as L-DOPA-
d e r i v e ds y n a p t i cD Al e v e l sw e r es h o w nt oi n c r e a s ew i t hp r o -
gression of the disease in a positron emission tomography
(PET) imaging study in PD patients [22].Parkinson’s Disease 3
Interestingly, Rylander and coworkers have recently
shown marked serotonin hyperinnervation in the lesioned
striatum of parkinsonian dyskinetic subjects across diﬀerent
species, including patients, thus raising the possibility that
serotonin neurons play a relevant role in the emergence of
LIDalsointhepatients[10,11,23].Thisstudysuggestedthat
L-DOPAtreatmentmaybeabletoprovokesproutingofsero-
tonin axon terminals and change their morphology, hence,
possibly enhancing the ﬂuctuations in extracellular DA con-
centration, consistent with ﬁndings of de la Fuente-Fernan-
dez and coworkers in their PET imaging study [22, 24].
In further experimental support for a detrimental eﬀect
of serotonin neurons on LID, grafted serotonin neurons,
which induced an intense hyperinnervation of the grafted
striatum, exacerbated LID in both partial and complete DA
lesioned rats [7, 25], raising the possibility that inclusion of
these cells in the grafted tissue may have detrimental eﬀects
on LID in grafted PD patients.
3. The Role of Serotonin Neurons in
theModulationof Graft-InducedDyskinesia
Transplantation of fetal ventral mesencephalic neurons is a
therapeutic approach to PD that has already been tested in
clinical trials [26–30]. While the variability in the outcome
of these studies halted further investigations, the presence
of highly responsive patients provided proof-of-concept that
this therapeutic intervention can be signiﬁcantly beneﬁcial.
Indeed, there is now general agreement that the reasons
accounting for the observed variability rely on the lack of
standardization of the cell preparations, surgical procedures,
aswellasontheselectionofpatients andpresenceorabsence
of postsurgical immunosuppressive treatment [31]. How-
ever, another element that has contributed to raise concern
about fetal transplantation is the appearance in a subset of
grafted patients of oﬀ-drug dyskinesia [29, 31–33] ,af o r mo f
involuntary movements that is phenotypically similar to the
one induced by L-DOPA but independent from its adminis-
tration. The recent ﬁndings on the role of serotonin neurons
in the induction of LID has led to hypothesize that serotonin
neurons included in the graft may also play a role in GID
[8, 16, 18].
In fact, serotonin neuroblasts are located in close vicinity
of the DA ones in the fetal ventral mesencephalic area that
is dissected for transplantation. Accordingly, about 50% of
grafted cells were found to be serotonin neurons in a post-
mortem analysis of the caudate-putamen of grafted patients
[34].
In possible support of this hypothesis, in a recent PET
study, Politis and colleagues have found intense serotonergic
hyperinnervation in the striatum of grafted patients showing
GID [12, 13]. Interestingly, administration of the partial
5-HT1A agonist buspirone suppressed GID in all tested
patients. An involvement of the serotonin neurons in GID is
further supported by the high serotonin transporter (SERT)/
DAT ratio found in one GID patient compared to both
healthy age-matched control and non-grafted PD patients
[12]. Thus, it is postulated that serotonin terminals may take
up DA released by the graft through SERT, and release DA,
as a false transmitter, away from the uptake site, in striatal
regions lacking suﬃcient DA innervation, thus, leading to
activation of supersensitive DA receptors. However, it should
be acknowledged that these clinical observations have been
made in a very few subjects, and further evidence should be
provided. In particular, it would be important to investigate
the state of the striatal serotonin innervation also in patients
free of GID.
Although spontaneous GID, that is dyskinesia in the
absence of any drug treatment, is inconsistent in grafted
rodents [35, 36], it does appear after administration of a low
dose of amphetamine [35, 37], which is known to evoke
massive DA release from grafted DA neurons [38]. These
abnormal movements can be scored with the same scale used
forLID[35,37],andarenowwidelyusedasaconvenientand
reproducible model of GID [7, 39–42]. While appearance of
GID in this rat model is clearly dependent on the presence
of an adequate number of DA neurons in the graft, we have
recently found a bidirectional modulatory eﬀect of endoge-
nous serotonin neurons on GID. In fact, reduction of seroto-
nin neuron activity, by a combination of 5-HT1A and 5-HT1B
receptor agonists, produced a signiﬁcant reduction of GID,
while increased serotonin neuron release by fenﬂuramine
exacerbated GID [43]. Strikingly, administration of a low
dose of buspirone (1mg/kg) completely suppressed GID, as
seeningraftedpatients.Interestingly,removaloftheendoge-
nousserotonininnervationbyspeciﬁctoxinlesionsappeared
to abolish the anti-GID eﬀect of the selective 5-HT1 agonists,
both in serotonin-containing and serotonin-free grafts, sug-
gesting that the modulatory eﬀect on GID may be due to the
endogenous rather than the graft-derived serotonin neurons,
at least in our experimental conditions. By contrast, neither
removal of the endogenous serotonin innervation nor pre-
treatment with the selective 5-HT1A antagonist WAY100135
reduced the anti-GID eﬃcacy of buspirone. In fact, bus-
pirone is also known to possess antagonistic properties on
D2 receptors [44–47]. In support for a D2-mediated eﬀect
of buspirone, similar anti-GID eﬀect was induced by a
low dose of the selective D2 receptor antagonist eticlopride
(0.03mg/kg). Thus, our data support a modulatory role of
the endogenous serotonin neurons on expression of GID, as
wellasapeculiarroleofD2 receptors.Indeed,bothbuspirone
and eticlopride were ineﬀective against LID at doses fully
suppressing GID [43].
Further work is required to understand whether inclu-
sion of serotonin neurons in the graft can be detrimental for
appearance of GID, although current experimental data do
not support this hypothesis.
4. Conclusion
Overall, loss of DA in basal ganglia circuits and DA replace-
ment by chronic L-DOPA administration result in complex
alterations in the parkinsonian brain, that aﬀect several
systems and key signaling proteins, most of which remain
poorly understood. DA released as a false transmitter from
serotonin neurons appears to play a key role in initiating
these events, at least in animal models. Serotonin neurons,4 Parkinson’s Disease
therefore, represent an intriguing pharmacological target to
treat already established LID and/or to prevent the events
leading to the appearance of LID from taking place. Recent
evidence suggests that serotonin neurons may also partici-
pate to the induction of dyskinesia seen in the oﬀ-state in
grafted PD patients. The upcoming new clinical trial, funded
bytheEuropeanCommunity,employingfetalventralmesen-
cephalic cells will answer the question whether optimization
of the surgical procedures and preparation of the grafted
material, including exclusion of serotonin neuroblasts, will
improve clinical outcome and avoid appearance of GID.
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